Sanofi (SNYNF) Capital Expenditures (2009 - 2021)

Sanofi (SNYNF) has 5 years of Capital Expenditures data on file, last reported at -$101.4 million in Q4 2021.

• Quarterly Capital Expenditures rose 3.84% year-over-year to -$101.4 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $653.3 million (down 66.86% YoY) and the FY2025 annual result came in at $4.1 billion, up 20.63% from the prior year.
• Capital Expenditures improved to -$101.4 million in Q4 2021 per SNYNF's latest filing, from -$105.4 million in the prior quarter.
• The five-year high for Capital Expenditures was -$90.5 million in Q4 2019, with the low at -$105.4 million in Q4 2020.
• Average Capital Expenditures over 3 years is -$99.1 million, with a median of -$101.4 million recorded in 2021.
• Year-over-year, Capital Expenditures dropped 16.41% in 2020 and rose 3.84% in 2021.
• Sanofi's Capital Expenditures stood at -$90.5 million in 2019, then decreased by 16.41% to -$105.4 million in 2020, then grew by 3.84% to -$101.4 million in 2021.
• Business Quant data shows SNYNF's Capital Expenditures at -$101.4 million in Q4 2021, -$105.4 million in Q4 2020, and -$90.5 million in Q4 2019.